17153-Leukemia-NA-1286

Leukemia

Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

  • Details

ClinicalTrials.gov ID: NCT03268954
Diagnosis Type: NA
USOR Number: 17153

  • Address

1845 W Orange Grove, Bldg 2
Tucson, AZ 85704
P: (520) 531-8967

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.